CPhI South East Asia indicates rapid growth for the ASEAN region

Record numbers, a focus on development initiatives and analysis of the regional harmonisation programme helps stimulate partnerships

CPhI South East Asia 2013, which ran from 20-22 March at the Jakarta International Expo in Indonesia, was the most successful so far, according to CPhI, a division of UBM Live. The event attracted more than 5,500 visitors from 51 countries and regions, meeting more than 260 exhibitors from 25 countries and regions around the world.

The strong international focus at CPhI South East Asia is representative of the expanding pharma sector within the region and was enhanced by new co-located events, including: PMEC for pharmaceutical machinery, laboratory equipment and analytical technology; and InnoPack South East Asia for innovative packaging and drug delivery solutions.

The pharma market in South East Asia is experiencing a very dynamic period with growth of both domestic manufacturing and international trade

‘The pharma market in South East Asia is experiencing a very dynamic period with growth of both domestic manufacturing and international trade,’ said Martin Wilson, UBM Live Brand Director. ‘We therefore designed CPhI South East Asia 2013 to reflect these sweeping changes and ran a series of high level conferences alongside the exhibition enabling participants to hear the latest thinking on pressing issues, including: the impending ASEAN harmonisation due in 2015; cross-border trade and regulatory arbitrage; IPR protection; and perspectives on the pharmerging markets, regional consumer trends, the growth of generics and regional manufacturing.’

A crucial element of the ASEAN region’s development, which is predicted to reach a market value of US$80bn by 2017, will be the establishing of close regional partnerships and cross-sharing of information between companies. CPhI South East Asia recognised this evolving landscape and is the only dedicated event for the region where ideas and business opportunities can be exchanged.

Furthermore, local governments have lent their support to the event as they aim to implement initiatives for increased domestic production, particularly focused on generics, and a tighter regulatory landscape aimed at reducing anticounterfeiting issues. Coupled with a growing economic affluence and cross border trade tis means the region is on the edge of an explosion of growth.

Our aim is to help facilitate the adoption of new technologies and partnerships needed to help meet the government-backed demands of an increasingly standardised regulatory arena and greater domestic production

The increase in exhibitors, internationally credible speakers and visitors highlights the immense strides countries here have made in manufacturing standards, increased commitment to standardised regulation, improved packaging technologies, and legislation protecting intellectual property – crucial to safeguarding innovation – and improving safety standards.

‘CPhI as a whole is mirroring changes in South East Asia and our aim is to help facilitate the adoption of new technologies and partnerships needed to help meet the government-backed demands of an increasingly standardised regulatory arena and greater domestic production of pharmaceuticals,’ Wilson said.

‘With a rapidly reforming healthcare landscape this event will continue to grow next year and help build the region as a manufacturing base and source of biotech and pharmaceutical innovation.’

CPhI South East Asia will return to the Jakarta International Expo from 20-22 May 2014 and UBM Live looks forward to bringing its international pharma event back to one of the world’s most dynamically evolving regions.

Companies